Botulinum toxin type F for treatment of dystonia: long-term experience.
The authors analyzed retrospectively the results of open-labeled botulinum toxin type F (BTXF) treatment for 1 year or longer in 18 BTXA-resistant patients. All patients except one primary nonresponder to BTXA improved initially with BTXF. Most patients continued to respond to BTXF for 1 year or longer, but four patients became resistant to BTXF. BTXF-resistant patients received a higher dose per treatment and a higher cumulative dose than BTXF-responsive patients. BTXF can be used for long-term treatment of dystonia. It seems prudent to limit BTX doses of all serotypes to the lowest necessary for clinical efficacy.
Chen
R
R
Human Motor Control Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892-1428, USA.
Karp
B I
BI
Hallett
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018726:Anti-Dyskinesia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001764:Blepharospasm / Q000188:drug therapy; D001905:Botulinum Toxins / Q000008:administration & dosage / Q000627:therapeutic use*; D004421:Dystonia / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014103:Torticollis / Q000188:drug therapy; D016896:Treatment Outcome
D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins; C096321:botulinum toxin type F